Understanding TAKHZYRO's Pharmacokinetics: What is the Half Life of TAKHZYRO?
•
4 min read
The medication TAKHZYRO (lanadelumab-flyo) has an approximate half-life of 14 days, which is a primary reason for its convenient and infrequent dosing schedule for patients with hereditary angioedema (HAE). This long-acting property allows for consistent therapeutic levels to be maintained in the body over an extended period.
